JoAl Mayor

687 total citations
17 papers, 122 citations indexed

About

JoAl Mayor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, JoAl Mayor has authored 17 papers receiving a total of 122 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in JoAl Mayor's work include HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (5 papers) and Gastric Cancer Management and Outcomes (5 papers). JoAl Mayor is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (5 papers) and Gastric Cancer Management and Outcomes (5 papers). JoAl Mayor collaborates with scholars based in United States, Spain and Italy. JoAl Mayor's co-authors include Christopher J. Endres, Anthony Lee, Luke Walker, Mehdi Karami, John H. Strickler, Tanios Bekaii‐Saab, Ajay K. Gopal, Leona Holmberg, Hao Sun and William Bensinger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

JoAl Mayor

16 papers receiving 121 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JoAl Mayor United States 7 76 41 31 23 17 17 122
Andrew Johns United States 10 163 2.1× 61 1.5× 46 1.5× 27 1.2× 5 0.3× 33 243
Anna Morelli Italy 7 56 0.7× 61 1.5× 31 1.0× 18 0.8× 3 0.2× 19 153
Esmée C. de Baat Netherlands 6 51 0.7× 57 1.4× 37 1.2× 10 0.4× 26 1.5× 7 208
Luca Campedel France 6 32 0.4× 42 1.0× 20 0.6× 10 0.4× 17 1.0× 26 93
Antonella Bruzzese Italy 6 33 0.4× 27 0.7× 47 1.5× 62 2.7× 7 0.4× 34 158
Ridhi Gupta United States 6 43 0.6× 46 1.1× 23 0.7× 31 1.3× 8 0.5× 14 166
Colin Hayward Switzerland 8 48 0.6× 30 0.7× 26 0.8× 129 5.6× 19 1.1× 22 198
G Cecchi United States 6 116 1.5× 67 1.6× 18 0.6× 12 0.5× 8 0.5× 9 198
Elles M. Screever Netherlands 10 52 0.7× 18 0.4× 40 1.3× 23 1.0× 14 0.8× 16 201
Roel van Kampen Netherlands 5 75 1.0× 12 0.3× 34 1.1× 10 0.4× 4 0.2× 8 167

Countries citing papers authored by JoAl Mayor

Since Specialization
Citations

This map shows the geographic impact of JoAl Mayor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JoAl Mayor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JoAl Mayor more than expected).

Fields of papers citing papers by JoAl Mayor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JoAl Mayor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JoAl Mayor. The network helps show where JoAl Mayor may publish in the future.

Co-authorship network of co-authors of JoAl Mayor

This figure shows the co-authorship network connecting the top 25 collaborators of JoAl Mayor. A scholar is included among the top collaborators of JoAl Mayor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JoAl Mayor. JoAl Mayor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mayor, JoAl, et al.. (2023). Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers. Drugs in R&D. 23(4). 411–419. 1 indexed citations
2.
Lee, Anthony, et al.. (2023). Pharmacokinetics and Safety of Tucatinib in Healthy Japanese and Caucasian Volunteers: Results From a Phase Ⅰ Study. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 54(5). 187–196. 1 indexed citations
3.
Lee, Anthony, et al.. (2022). Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers. Clinical Pharmacokinetics. 61(10). 1417–1426. 11 indexed citations
4.
Lee, Anthony, et al.. (2022). The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment. Clinical Pharmacokinetics. 61(12). 1761–1770. 5 indexed citations
5.
Catenacci, Daniel V.T., John H. Strickler, Yoshiaki Nakamura, et al.. (2022). MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress.. Journal of Clinical Oncology. 40(4_suppl). TPS371–TPS371. 13 indexed citations
6.
7.
8.
Lee, Anthony, et al.. (2021). Abstract 1371: Pharmacokinetics of tucatinib in healthy and hepatically-impaired volunteers. Cancer Research. 81(13_Supplement). 1371–1371. 1 indexed citations
9.
Catenacci, Daniel V.T., John H. Strickler, Yoshiaki Nakamura, et al.. (2021). 1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. Annals of Oncology. 32. S1071–S1072. 1 indexed citations
10.
Strickler, John H., Yoshiaki Nakamura, Takayuki Yoshino, et al.. (2021). MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.. Journal of Clinical Oncology. 39(3_suppl). TPS252–TPS252. 17 indexed citations
11.
Lee, Anthony, et al.. (2020). Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. The Journal of Clinical Pharmacology. 61(4). 461–471. 22 indexed citations
12.
Lee, Anthony, et al.. (2020). Abstract 3016: Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers. Cancer Research. 80(16_Supplement). 3016–3016. 3 indexed citations
13.
Mayor, JoAl, et al.. (2017). Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists. Journal of Oncology Pharmacy Practice. 25(3). 558–566. 12 indexed citations
14.
Saunders, Ila M., et al.. (2015). Results of the American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Practice Survey – Understanding Today to Meet the Needs of Tomorrow. Biology of Blood and Marrow Transplantation. 21(2). S370–S371. 1 indexed citations
15.
Gopal, Ajay K., Mehdi Karami, JoAl Mayor, et al.. (2012). The effective use of plerixafor as a real‐time rescue strategy for patients poorly mobilizing autologous CD34+ cells. Journal of Clinical Apheresis. 27(2). 81–87. 21 indexed citations
16.
17.
Arenas, Joaquı́n, JoAl Mayor, F.-Javier Gella, et al.. (1988). Arylsulfatase A in urine of patients with urothelial tumors. Clinical Biochemistry. 21(1). 73–77. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew Johns Breakdown of academic impact, for papers by Anna Morelli Breakdown of academic impact, for papers by Esmée C. de Baat Breakdown of academic impact, for papers by Luca Campedel Breakdown of academic impact, for papers by Antonella Bruzzese Breakdown of academic impact, for papers by Ridhi Gupta Breakdown of academic impact, for papers by Colin Hayward Breakdown of academic impact, for papers by G Cecchi Breakdown of academic impact, for papers by Elles M. Screever Breakdown of academic impact, for papers by Roel van Kampen
Rankless by CCL
2026